AHA: In Cardiac Sx, Restrictive Red-Cell Transfusion Noninferior
MONDAY, Nov. 13, 2017 -- A restrictive threshold for red-cell transfusion is noninferior to a liberal threshold for patients undergoing cardiac surgery with moderate to high risk of death, according to a study published online Nov. 12 in the New England Journal of Medicine to coincide with the American Heart Association's Scientific Sessions, being held Nov. 11 to 15 in Anaheim, California.
C. David Mazer, M.D., from the Keenan Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital in Canada, and colleagues conducted a multicenter noninferiority trial involving 5,243 adults undergoing cardiac surgery who had a European System for Cardiac Operative Risk Evaluation score of 6 or higher. Participants were randomized to a restrictive red-cell transfusion threshold or a liberal red-cell transfusion threshold. The primary outcome was death from any cause, myocardial infarction, stroke, or new-onset renal failure with dialysis by either day 28 or hospital discharge, whichever was first.
The researchers found that the primary outcome occurred in 11.4 and 12.5 percent of patients in the restrictive-threshold and liberal-threshold groups, respectively (absolute risk difference, −1.11 percentage points; 95 percent confidence interval, −2.93 to 0.72; odds ratio, 0.9; 95 percent confidence interval, 0.76 to 1.07; P < 0.001 for noninferiority). Mortality was 3 and 3.6 percent in the restrictive- and liberal-threshold groups, respectively (odds ratio, 0.85; 95 percent confidence interval, 0.62 to 1.16).
"A restrictive strategy regarding red-cell transfusion was noninferior to a liberal strategy with respect to the composite outcome of death from any cause, myocardial infarction, stroke, or new-onset renal failure with dialysis, with less blood transfused," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: November 2017
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.